86 related articles for article (PubMed ID: 26689589)
1. APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment.
Sjödin S; Andersson KK; Mercken M; Zetterberg H; Borghys H; Blennow K; Portelius E
Alzheimers Res Ther; 2015 Dec; 7(1):77. PubMed ID: 26689589
[TBL] [Abstract][Full Text] [Related]
2. An NSAID-like compound, FT-9, preferentially inhibits gamma-secretase cleavage of the amyloid precursor protein compared to its effect on amyloid precursor-like protein 1.
Sala Frigerio C; Kukar TL; Fauq A; Engel PC; Golde TE; Walsh DM
Biochemistry; 2009 Nov; 48(46):10894-904. PubMed ID: 19821615
[TBL] [Abstract][Full Text] [Related]
3. How Modulator Binding at the Amyloidβ-γ-Secretase Interface Enhances Substrate Binding and Attenuates Membrane Distortion.
Chen SY; Koch M; Chávez-Gutiérrez L; Zacharias M
J Med Chem; 2023 Dec; 66(24):16772-16782. PubMed ID: 38059872
[TBL] [Abstract][Full Text] [Related]
4. Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator.
Jung JI; Price AR; Ladd TB; Ran Y; Park HJ; Ceballos-Diaz C; Smithson LA; Hochhaus G; Tang Y; Akula R; Ba S; Koo EH; Shapiro G; Felsenstein KM; Golde TE
Mol Neurodegener; 2015 Jul; 10():29. PubMed ID: 26169917
[TBL] [Abstract][Full Text] [Related]
5. Steroids as γ-secretase modulators.
Jung JI; Ladd TB; Kukar T; Price AR; Moore BD; Koo EH; Golde TE; Felsenstein KM
FASEB J; 2013 Sep; 27(9):3775-85. PubMed ID: 23716494
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses.
Lu Y; Riddell D; Hajos-Korcsok E; Bales K; Wood KM; Nolan CE; Robshaw AE; Zhang L; Leung L; Becker SL; Tseng E; Barricklow J; Miller EH; Osgood S; O'Neill BT; Brodney MA; Johnson DS; Pettersson M
J Pharmacol Exp Ther; 2012 Aug; 342(2):366-75. PubMed ID: 22562771
[TBL] [Abstract][Full Text] [Related]
7. Discovery of aryl aminothiazole γ-secretase modulators with novel effects on amyloid β-peptide production.
Bhattarai S; Liu L; Wolfe MS
Bioorg Med Chem Lett; 2021 Dec; 54():128446. PubMed ID: 34767913
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Modulatory Role of E2012 on the γ-Secretase-Substrate Interaction.
Guzmán-Ocampo DC; Aguayo-Ortiz R; Dominguez L
J Chem Inf Model; 2024 May; 64(9):3855-3864. PubMed ID: 38623052
[TBL] [Abstract][Full Text] [Related]
9. NGP 555, a γ-secretase modulator, shows a beneficial shift in the ratio of amyloid biomarkers in human cerebrospinal fluid at safe doses.
Kounnas MZ; Durakoglugil MS; Herz J; Comer WT
Alzheimers Dement (N Y); 2019; 5():458-467. PubMed ID: 31921961
[TBL] [Abstract][Full Text] [Related]
10. Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease.
Nordvall G; Lundkvist J; Sandin J
Front Mol Neurosci; 2023; 16():1279740. PubMed ID: 37908487
[TBL] [Abstract][Full Text] [Related]
11. Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780.
Toyn JH; Thompson LA; Lentz KA; Meredith JE; Burton CR; Sankaranararyanan S; Guss V; Hall T; Iben LG; Krause CM; Krause R; Lin XA; Pierdomenico M; Polson C; Robertson AS; Denton RR; Grace JE; Morrison J; Raybon J; Zhuo X; Snow K; Padmanabha R; Agler M; Esposito K; Harden D; Prack M; Varma S; Wong V; Zhu Y; Zvyaga T; Gerritz S; Marcin LR; Higgins MA; Shi J; Wei C; Cantone JL; Drexler DM; Macor JE; Olson RE; Ahlijanian MK; Albright CF
Int J Alzheimers Dis; 2014; 2014():431858. PubMed ID: 25097793
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer's Disease.
Pettersson M; Johnson DS; Humphrey JM; Am Ende CW; Butler TW; Dorff PH; Efremov IV; Evrard E; Green ME; Helal CJ; Kauffman GW; Mullins PB; Navaratnam T; O'Donnell CJ; O'Sullivan TJ; Patel NC; Stepan AF; Stiff CM; Subramanyam C; Trapa P; Tran TP; Vetelino BC; Yang E; Xie L; Pustilnik LR; Steyn SJ; Wood KM; Bales KR; Hajos-Korcsok E; Verhoest PR
J Med Chem; 2024 Jun; ():. PubMed ID: 38848667
[TBL] [Abstract][Full Text] [Related]
13. Initial Optimization of a New Series of γ-Secretase Modulators Derived from a Triterpene Glycoside.
Fuller NO; Hubbs JL; Austin WF; Creaser SP; McKee TD; Loureiro RM; Tate B; Xia W; Ives JL; Findeis MA; Bronk BS
ACS Med Chem Lett; 2012 Nov; 3(11):908-13. PubMed ID: 24900406
[TBL] [Abstract][Full Text] [Related]
14. Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacy.
Pettersson M; Johnson DS; Rankic DA; Kauffman GW; Am Ende CW; Butler TW; Boscoe B; Evrard E; Helal CJ; Humphrey JM; Stepan AF; Stiff CM; Yang E; Xie L; Bales KR; Hajos-Korcsok E; Jenkinson S; Pettersen B; Pustilnik LR; Ramirez DS; Steyn SJ; Wood KM; Verhoest PR
Medchemcomm; 2017 Apr; 8(4):730-743. PubMed ID: 30108792
[TBL] [Abstract][Full Text] [Related]
15. Phenyl bioisosteres in medicinal chemistry: discovery of novel γ-secretase modulators as a potential treatment for Alzheimer's disease.
Ratni H; Baumann K; Bellotti P; Cook XA; Green LG; Luebbers T; Reutlinger M; Stepan AF; Vifian W
RSC Med Chem; 2021 May; 12(5):758-766. PubMed ID: 34124674
[TBL] [Abstract][Full Text] [Related]
16. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
[TBL] [Abstract][Full Text] [Related]
17. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
[TBL] [Abstract][Full Text] [Related]
18. Wide-Ranging Effects on the Brain Proteome in a Transgenic Mouse Model of Alzheimer's Disease Following Treatment with a Brain-Targeting Somatostatin Peptide.
Rofo F; Sandbaumhüter FA; Chourlia A; Metzendorf NG; Morrison JI; Syvänen S; Andrén PE; Jansson ET; Hultqvist G
ACS Chem Neurosci; 2021 Jul; 12(13):2529-2541. PubMed ID: 34170117
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive systematic review of CSF proteins and peptides that define Alzheimer's disease.
Pedrero-Prieto CM; García-Carpintero S; Frontiñán-Rubio J; Llanos-González E; Aguilera García C; Alcaín FJ; Lindberg I; Durán-Prado M; Peinado JR; Rabanal-Ruiz Y
Clin Proteomics; 2020; 17():21. PubMed ID: 32518535
[TBL] [Abstract][Full Text] [Related]
20. Combined proteomic and metabolomic analyses of cerebrospinal fluid from mice with ischemic stroke reveals the effects of a Buyang Huanwu decoction in neurodegenerative disease.
Hsu WH; Shen YC; Shiao YJ; Kuo CH; Lu CK; Lin TY; Ku WC; Lin YL
PLoS One; 2019; 14(1):e0209184. PubMed ID: 30645580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
